Patient baseline characteristics
| . | Total (N = 228) . |
|---|---|
| Age, y | |
| Mean (SD) | 47.9 (18.3) |
| Median (IQR) | 48.0 (31.0-62.0) |
| Age categories, n (%) | |
| 18-49 y | 117 (51.3) |
| 50-64 y | 66 (28.9) |
| 65-74 y | 26 (11.4) |
| ≥75 y | 19 (8.3) |
| Gender, n(%) | |
| Male | 84 (36.8) |
| Female | 144 (63.2) |
| Race, n (%) | |
| Caucasian | 101 (44.3) |
| Black | 2 (0.9) |
| Asian | 92 (40.4) |
| Other | 33 (14.5) |
| Ethnicity, n (%) | |
| Arabic | 47 (20.6) |
| East Asian | 53 (23.2) |
| Southeast Asian | 29 (12.7) |
| South Asian | 11 (4.8) |
| Egyptian | 25 (11.0) |
| Turkish | 57 (25.0) |
| Other | 6 (2.6) |
| Time since first diagnosis, y | |
| Mean (SD) | 5.8 (7.6) |
| Median (IQR) | 2.6 (0.5-8.2) |
| Patients with thromboembolic events in the last 12 mo, n (%) | 8 (3.5) |
| Patients with prior splenectomy, n (%) | 54 (23.7) |
| Bleeding events in the last 12 mo, n (%) | 88 (38.6) |
| Mean (SD) | 1.4 (0.7) |
| Median (IQR) | 1.0 (1.0-2.0) |
| Grade 1 | 61 (26.8) |
| Grade 2 | 22 (9.6) |
| Grade 3 | 8 (3.5) |
| Grade 4 | 2 (0.9) |
| Unknown | 1 (0.4) |
| Platelet transfusions,∗ n | 47 |
| Mean (SD) | 7.0 (8.2) |
| Median (IQR) | 3.0 (1.0-10.0) |
| RBC transfusions,∗ n | 17 |
| Mean (SD) | 2.6 (1.7) |
| Median (min, max) | 2.0 (1.0, 6.0) |
| Whole blood transfusions,∗ n | 1 |
| Mean (SD) | 2.0 (n.a.) |
| Median (IQR) | 2.0 (2.0-2.0) |
| Patients with prior eltrombopag treatment,† n | 19 |
| Cycles,‡ mean (SD) | 1.1 (0.2) |
| Cycles,‡ median (IQR) | 1.0 (1.0-1.0) |
| Duration of last treatment cycle‡ in days | |
| Mean (SD) | 233.9 (410.9) |
| Median (IQR) | 85.0 (31.0-217.0) |
| Maximum daily dose (mg) of the last treatment cycle‡ | |
| Mean (SD) | 51.3 (13.1) |
| Median (IQR) | 50.0 (50.0-50.0) |
| Response, n (%) | |
| Platelet response | 2 (0.9) |
| Complete platelet response | 6 (2.6) |
| No response | 8 (3.5) |
| Missing | 3 (1.3) |
| Not applicable | 209 (91.7) |
| Prior ITP medications, n (%) | |
| 0 | 40 (17.5) |
| 1 | 83 (36.4) |
| 2 | 55 (24.1) |
| 3 | 30 (13.2) |
| ≥4 | 20 (8.8) |
| . | Total (N = 228) . |
|---|---|
| Age, y | |
| Mean (SD) | 47.9 (18.3) |
| Median (IQR) | 48.0 (31.0-62.0) |
| Age categories, n (%) | |
| 18-49 y | 117 (51.3) |
| 50-64 y | 66 (28.9) |
| 65-74 y | 26 (11.4) |
| ≥75 y | 19 (8.3) |
| Gender, n(%) | |
| Male | 84 (36.8) |
| Female | 144 (63.2) |
| Race, n (%) | |
| Caucasian | 101 (44.3) |
| Black | 2 (0.9) |
| Asian | 92 (40.4) |
| Other | 33 (14.5) |
| Ethnicity, n (%) | |
| Arabic | 47 (20.6) |
| East Asian | 53 (23.2) |
| Southeast Asian | 29 (12.7) |
| South Asian | 11 (4.8) |
| Egyptian | 25 (11.0) |
| Turkish | 57 (25.0) |
| Other | 6 (2.6) |
| Time since first diagnosis, y | |
| Mean (SD) | 5.8 (7.6) |
| Median (IQR) | 2.6 (0.5-8.2) |
| Patients with thromboembolic events in the last 12 mo, n (%) | 8 (3.5) |
| Patients with prior splenectomy, n (%) | 54 (23.7) |
| Bleeding events in the last 12 mo, n (%) | 88 (38.6) |
| Mean (SD) | 1.4 (0.7) |
| Median (IQR) | 1.0 (1.0-2.0) |
| Grade 1 | 61 (26.8) |
| Grade 2 | 22 (9.6) |
| Grade 3 | 8 (3.5) |
| Grade 4 | 2 (0.9) |
| Unknown | 1 (0.4) |
| Platelet transfusions,∗ n | 47 |
| Mean (SD) | 7.0 (8.2) |
| Median (IQR) | 3.0 (1.0-10.0) |
| RBC transfusions,∗ n | 17 |
| Mean (SD) | 2.6 (1.7) |
| Median (min, max) | 2.0 (1.0, 6.0) |
| Whole blood transfusions,∗ n | 1 |
| Mean (SD) | 2.0 (n.a.) |
| Median (IQR) | 2.0 (2.0-2.0) |
| Patients with prior eltrombopag treatment,† n | 19 |
| Cycles,‡ mean (SD) | 1.1 (0.2) |
| Cycles,‡ median (IQR) | 1.0 (1.0-1.0) |
| Duration of last treatment cycle‡ in days | |
| Mean (SD) | 233.9 (410.9) |
| Median (IQR) | 85.0 (31.0-217.0) |
| Maximum daily dose (mg) of the last treatment cycle‡ | |
| Mean (SD) | 51.3 (13.1) |
| Median (IQR) | 50.0 (50.0-50.0) |
| Response, n (%) | |
| Platelet response | 2 (0.9) |
| Complete platelet response | 6 (2.6) |
| No response | 8 (3.5) |
| Missing | 3 (1.3) |
| Not applicable | 209 (91.7) |
| Prior ITP medications, n (%) | |
| 0 | 40 (17.5) |
| 1 | 83 (36.4) |
| 2 | 55 (24.1) |
| 3 | 30 (13.2) |
| ≥4 | 20 (8.8) |
n.a., not applicable; RBC, red blood cell.
Number of transfusions for patients with ≥1 transfusion.
Prior eltrombopag treatment refers to patients who had received and discontinued eltrombopag previously but did not restart it ≥12 weeks before the eltrombopag cycle captured in the study, as described in “Methods.”
A cycle was defined as repeated administration(s) after interruption of ≥12 weeks.